Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.

Vandenbark AA, Culbertson NE, Bartholomew RM, Huan J, Agotsch M, LaTocha D, Yadav V, Mass M, Whitham R, Lovera J, Milano J, Theofan G, Chou YK, Offner H, Bourdette DN.

Immunology. 2008 Jan;123(1):66-78. Epub 2007 Oct 16.

2.

A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis.

Bourdette DN, Edmonds E, Smith C, Bowen JD, Guttmann CR, Nagy ZP, Simon J, Whitham R, Lovera J, Yadav V, Mass M, Spencer L, Culbertson N, Bartholomew RM, Theofan G, Milano J, Offner H, Vandenbark AA.

Mult Scler. 2005 Oct;11(5):552-61.

PMID:
16193893
3.

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.

Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, Goh LE, Andersson J, Tsoukas C, Sonnerborg A, Tambussi G, Girard PM, Bloch M, Battegay M, Carter N, El Habib R, Theofan G, Cooper DA, Perrin L; QUEST Study Group.

J Infect Dis. 2005 Aug 15;192(4):607-17. Epub 2005 Jul 15.

PMID:
16028129
4.

HIV-specific immunity during structured antiviral drug treatment interruption.

Moss RB, Brandt C, Giermakowska WK, Savary JR, Theofan G, Zanetti M, Carlo DJ, Wallace MR.

Vaccine. 2003 Mar 7;21(11-12):1066-71.

PMID:
12559781
5.

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.

Moss RB, Wallace MR, Giermakowska WK, Webb E, Savary J, Chamberlin-Brandt C, Theofan G, Musil R, Richieri SP, Jensen FC, Carlo DJ.

J Infect Dis. 1999 Sep;180(3):641-8.

PMID:
10438350
6.

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection.

Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price LD, Cox JH, Jarosinski P, Walsek CM, Brouwers P, Venzon DJ, Xu J, Pizzo PA, Moss RB, Robb ML, Wood LV.

J Infect Dis. 1999 Sep;180(3):626-40.

PMID:
10438349
7.

Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.

Moss RB, Li L, Giermakowska WK, Lanza P, Turner JL, Wallace MR, Jensen FC, Richieri SP, Daigle AE, Theofan G, Carlo DJ.

J Hum Virol. 1998 Jan-Feb;1(2):77-81.

PMID:
10195235
8.

Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.

Churdboonchart V, Moss RB, Sirawaraporn W, Smutharaks B, Sutthent R, Jensen FC, Vacharak P, Grimes J, Theofan G, Carlo DJ.

AIDS. 1998 Aug 20;12(12):1521-7.

PMID:
9727574
9.

A primer on HIV type 1-specific immune function and REMUNE.

Moss RB, Giermakowska WK, Savary JR, Theofan G, Daigle AE, Richieri SP, Jensen FC, Carlo DJ.

AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S167-75. Review.

PMID:
9672235
10.

Safety and immunogenicity of REMUNE in HIV-infected Thai subjects.

Limsuwan A, Churdboonchart V, Moss RB, Sirawaraporn W, Sutthent R, Smutharaks B, Glidden D, Trauger R, Theofan G, Carlo D.

Vaccine. 1998 Jan-Feb;16(2-3):142-9.

PMID:
9607022
11.
12.

HIV-1-Specific Functional Immune Measurements as Markers of Disease Progression.

Moss RB, Richieri SP, Ferre F, Daigle AE, Trauger R, Theofan G, Giermakowska W, Lanza P, Brostoff S, Carlo DJ, Jensen FC.

J Biomed Sci. 1997 Jul-Aug;4(4):127-131.

PMID:
11725144
13.

Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection.

Moss RB, Trauger RJ, Giermakowska WK, Turner JL, Wallace MR, Jensen FC, Richieri SP, Ferre F, Daigle AE, Duffy C, Theofan G, Carlo DJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 1;14(4):343-50.

PMID:
9111476
14.

Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein. Implications in biological activity.

Abrahamson SL, Wu HM, Williams RE, Der K, Ottah N, Little R, Gazzano-Santoro H, Theofan G, Bauer R, Leigh S, Orme A, Horwitz AH, Carroll SF, Dedrick RL.

J Biol Chem. 1997 Jan 24;272(4):2149-55.

16.

Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein.

Horwitz AH, Leigh SD, Abrahamson S, Gazzano-Santoro H, Liu PS, Williams RE, Carroll SF, Theofan G.

Protein Expr Purif. 1996 Aug;8(1):28-40.

PMID:
8812832
17.
18.

Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria.

Gazzano-Santoro H, Mészáros K, Birr C, Carroll SF, Theofan G, Horwitz AH, Lim E, Aberle S, Kasler H, Parent JB.

Infect Immun. 1994 Apr;62(4):1185-91.

19.

An amino-terminal fragment of human lipopolysaccharide-binding protein retains lipid A binding but not CD14-stimulatory activity.

Theofan G, Horwitz AH, Williams RE, Liu PS, Chan I, Birr C, Carroll SF, Mészáros K, Parent JB, Kasler H, et al.

J Immunol. 1994 Apr 1;152(7):3623-9.

PMID:
7511654
20.

A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS.

Mészáros K, Parent JB, Gazzano-Santoro H, Little R, Horwitz A, Parsons T, Theofan G, Grinna L, Weickmann J, Elsbach P, et al.

J Leukoc Biol. 1993 Dec;54(6):558-63.

PMID:
8245707
21.

Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia.

Kohn FR, Ammons WS, Horwitz A, Grinna L, Theofan G, Weickmann J, Kung AH.

J Infect Dis. 1993 Nov;168(5):1307-10.

PMID:
8228369
22.

High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide.

Gazzano-Santoro H, Parent JB, Grinna L, Horwitz A, Parsons T, Theofan G, Elsbach P, Weiss J, Conlon PJ.

Infect Immun. 1992 Nov;60(11):4754-61.

24.
26.
27.

Expression of calbindin-D28K mRNA as a function of altered serum calcium and phosphorus levels in vitamin D-replete chick intestine.

Theofan G, King MW, Hall AK, Norman AW.

Mol Cell Endocrinol. 1987 Dec;54(2-3):135-40.

PMID:
3691957
28.

1,25-Dihydroxyvitamin D3 regulates tubulin expression in chick intestine.

Nemere I, Theofan G, Norman AW.

Biochem Biophys Res Commun. 1987 Nov 13;148(3):1270-6.

PMID:
3689395
29.
31.

Supplemental Content

Loading ...
Support Center